Table 3.
Risk of different types of adverse events according to study characteristics.
| Comparison | Risk of Adverse Event Requiring Treatment | Risk of Adverse Event Requiring Epinephrine | ||||||
|---|---|---|---|---|---|---|---|---|
| Studies | % (95% CI) | I2 | p value | Studies | % (95% CI) | I2 | p value | |
| Overall | ||||||||
| 7 | 38.3 (25.1–52.4) | 79.5 | NA | 26 | 7.6 (4.5–11.4) | 75.5 | NA | |
| Rush Phase | ||||||||
| Yes | 3 | 53.7 (43.4–63.9) | NA | 0.005 | 17 | 11.6 (8.1–15.6) | 57.8 | 0.001 |
| No | 4 | 28.1 (15.7–42.4) | 68.9 | 9 | 2.3 (0.1–6.1) | 53.2 | ||
| Co-Treatment | ||||||||
| Yes | 1 | 41 (27.1–56.6) | NA | NA | 7 | 6.6 (1.9–13.2) | 52.7 | 0.677 |
| No | 6 | 37.8 (22.4–54.5) | 82.6 | 20 | 8.0 (4.3–12.5) | 77.4 | ||
| Intervention Blinding | ||||||||
| Yes | 2 | 41.9 (28.3–56.2) | NA | 0.651 | 6 | 7.3 (2.5–13.7) | 59.4 | 0.825 |
| No | 5 | 36.7 (19.8–55.4) | 85.6 | 20 | 7.9 (3.9–12.8) | 78.8 | ||
| Maintenance Dose (mg/day) | ||||||||
| <1000 | 5 | 40.5 (24.6–57.5) | 82.7 | 0.880 | 13 | 4.0 (1.1–8.2) | 74.8 | 0.001 |
| ≥1000 | 3 | 38.0 (16.2–62.3) | NA | 14 | 13.7 (9.6–18.3) | 37.7 | ||
| Entry OFC | ||||||||
| DBPCFC | 2 | 24.9 (17.8–32.8) | NA | 0.001 | 13 | 6.8 (3.2–11.4) | 63.7 | 0.784 |
| Open | 3 | 37.1 (17.7–58.6) | NA | 6 | 6.1 (0.2–16.7) | 79.1 | ||
| None | 2 | 53.5 (40.3–66.5) | NA | 7 | 10.3 (3.2–20.2) | 82.8 | ||
| Baseline psIgE (kU/L) | ||||||||
| <60 | 3 | 28.6 (7.9–55.1) | NA | 0.215 | 10 | 2.8 (0.4–6.5) | 43.7 | 0.018 |
| ≥60 | 4 | 46.1 (37.3–55.0) | 0 | 14 | 9.1 (5.7–13.2) | 46.0 | ||
| Baseline SPT (mm) | ||||||||
| <12 | 5 | 38.6 (24.0–54.2) | 79.2 | NA | 11 | 7.1 (3.3–12.1) | 76.4 | 0.548 |
| ≥12 | 1 | 14.3 (4.0–39.9) | NA | 8 | 8.3 (3.3–14.9) | 31.4 | ||
Abbreviations: OFC, oral food challenge; DBPCFC, double blind placebo controlled food challenge; psIgE, peanut specific IgE; SPT, skin prick test.